Interpretation of the 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer:perioperative assessment and management of parathyroid function and precision individualized management of postoperative TSH suppression in adults with differentiated thyroid cancer
10.19401/j.cnki.1007-3639.2025.09.004
- VernacularTitle:《2025版美国甲状腺学会成人分化型甲状腺癌管理指南》解读:围手术期甲状旁腺功能的评估、处理及术后TSH抑制的精准个体化管理
- Author:
Yiming WU
1
;
Chuyao FENG
;
Ying GAO
;
Xiaohong WU
Author Information
1. 北京大学第一医院内分泌科,北京 100034
- Publication Type:Journal Article
- Keywords:
Differentiated thyroid cancer;
Perioperative period;
Parathyroid function;
Thyroid-stimulating hormone suppression;
Individualized management
- From:
China Oncology
2025;35(9):841-849
- CountryChina
- Language:Chinese
-
Abstract:
In recent years,the incidence of differentiated thyroid cancer(DTC)continues to rise,with increasing attention to perioperative management and postoperative thyroid-stimulating hormone(TSH)suppression therapy strategies.The American Thyroid Association(ATA)released the"2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer"in 2025,which include significant updates on perioperative parathyroid function protection and TSH suppression therapy.In terms of perioperative management,the 2025 ATA guidelines recommend intraoperative application of novel methods to identify and protect the parathyroid glands,and adoption of parathyroid hormone(PTH)-guided calcium and vitamin D supplementation protocols following total thyroidectomy.Regarding TSH suppression therapy,the 2025 ATA guidelines eliminate specific TSH target value recommendations for initial treatment,emphasizing that TSH targets should be dynamically adjusted based on patients'initial recurrence risk and treatment response to achieve individualized management and avoid overtreatment.
